AMG176, with the CAS number 1883727-34-1, is a small molecule that functions as a selective inhibitor of the B-cell lymphoma 2 (BCL-2) protein. This compound is primarily investigated for its potential therapeutic applications in treating various hematological malignancies, particularly those associated with BCL-2 overexpression, such as certain types of leukemia and lymphoma. AMG176 exhibits a unique mechanism of action by promoting apoptosis in cancer cells, thereby inhibiting tumor growth. Its selectivity for BCL-2 over other members of the BCL-2 family is a significant characteristic, as it aims to minimize off-target effects and enhance therapeutic efficacy. Preclinical studies have demonstrated its ability to induce cell death in BCL-2-dependent cancer cell lines, and it is often evaluated in combination with other therapies to improve treatment outcomes. As research continues, AMG176 represents a promising avenue in the development of targeted cancer therapies, contributing to the growing field of precision medicine.

AMG176

1883727-34-1: AMG176, with the CAS number 1883727-34-1, is a small molecule that functions as a selective inhibitor of the B-cell lymphoma 2 (BCL-2) protein. This compound is primarily investigated for its potential therapeutic applications in treating various hematological malignancies, particularly those associated with BCL-2 overexpression, such as certain types of leukemia and lymphoma. AMG176 exhibits a unique mechanism of action by promoting apoptosis in cancer cells, thereby inhibiting tumor growth. Its selectivity for BCL-2 over other members of the BCL-2 family is a significant characteristic, as it aims to minimize off-target effects and enhance therapeutic efficacy. Preclinical studies have demonstrated its ability to induce cell death in BCL-2-dependent cancer cell lines, and it is often evaluated in combination with other therapies to improve treatment outcomes. As research continues, AMG176 represents a promising avenue in the development of targeted cancer therapies, contributing to the growing field of precision medicine.

Tapotoclax

Tapotoclax (AMG-176) is an orally active MCL1 inhibitor for the study of myeloid leukemia.

AMG 176 is a potent and selective inhibitor of the Src kinase. It has been shown to inhibit the proliferation of cancer cells in vitro and induce apoptosis in vivo. AMG 176 may be used as a potential therapeutic for cancer treatment.

CAS 1883727-34-1

AMG176

Tapotoclax

Ref: 54-BUP01525

Tapotoclax

Ref: TM-T14213

AMG 176

Ref: 3D-BA166832